Accès gratuit
Volume 25, Numéro 3, Mai 2016
Page(s) 287 - 295
Section Mise Au Point / Update
Publié en ligne 18 février 2016
  • Dellinger RP, Levy MM, Rhodes A, et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228 [CrossRef] [PubMed] [Google Scholar]
  • Kumar A, Ellis P, Arabi Y, et al (2009) Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 136:1237–48 [CrossRef] [PubMed] [Google Scholar]
  • Meehan TP, Fine MJ, Krumholz HM, et al (1997) Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 278:2080–4 [CrossRef] [PubMed] [Google Scholar]
  • Dennesen PJ, van der Ven AJ, Kessels AG, et al (2001) Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 163:1371–5 [CrossRef] [PubMed] [Google Scholar]
  • Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363:600–7 [CrossRef] [PubMed] [Google Scholar]
  • Mandell LA, Bartlett JG, Dowell SF, et al (2003) Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37:1405–33 [CrossRef] [PubMed] [Google Scholar]
  • File TM Jr (2004) Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 39:S159–S64 [CrossRef] [PubMed] [Google Scholar]
  • Niederman MS, Mandell LA, Anzueto A, et al (2001) Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730–54 [CrossRef] [PubMed] [Google Scholar]
  • Corona A, Wilson AP, Grassi M, et al (2004) Prospective audit of bacteraemia management in a university hospital ICU using a general strategy of short-course monotherapy. J Antimicrob Chemother 54:809–17 [CrossRef] [PubMed] [Google Scholar]
  • Sawyer RG, Claridge JA, Nathens AB, et al (2015) Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med 372:1996–2005 [CrossRef] [PubMed] [Google Scholar]
  • Bassetti M, De Waele JJ, Eggimann P, et al (2015) Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 41:776–95 [CrossRef] [PubMed] [Google Scholar]
  • Paterson DL, Rice LB (2003) Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis 36:1006–12 [CrossRef] [PubMed] [Google Scholar]
  • 2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95 [CrossRef] [PubMed] [Google Scholar]
  • Christ-Crain M, Opal SM (2010) Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 14:203 [CrossRef] [PubMed] [Google Scholar]
  • Shehabi Y, Seppelt I (2008) Pro/Con debate: is procalcitonin useful for guiding antibiotic decision making in critically ill patients? Crit Care 12:211 [CrossRef] [PubMed] [Google Scholar]
  • Barraud D, Gibot S (2009) Apport des marqueurs biologiques de l’infection aux urgences et en réanimation. In: Boles JM, Bollaert PE, Jaeger A, et al (eds) Réanimation Médicale. Masson, Paris, pp 988–92 [Google Scholar]
  • Kaplan JM, Wong HR (2011) Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med 12:165–173 [CrossRef] [PubMed] [Google Scholar]
  • Schuetz P, Christ-Crain M, Muller B (2009) Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype? Swiss Med Wkly 139:318–26 [PubMed] [Google Scholar]
  • Gibot S, Bene MC, Noel R, et al (2012) Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 186:65–71 [CrossRef] [PubMed] [Google Scholar]
  • Dupuy AM, Kuster N, Lizard G, et al (2013) Performance evaluation of human cytokines profiles obtained by various multiplexed-based technologies underlines a need for standardization. Clin Chem Lab Med 51:1385–93 [CrossRef] [PubMed] [Google Scholar]
  • Pierrakos C, Vincent JL (2010) Sepsis biomarkers: a review. Crit Care 14:R15 [CrossRef] [PubMed] [Google Scholar]
  • Ehl S, Gering B, Bartmann P, et al (1997) C reactive protein is a useful marker for guiding duration of antibiotic therapy in suspected neonatal bacterial infection. Pediatrics 99:216–21 [CrossRef] [PubMed] [Google Scholar]
  • Bomela HN, Ballot DE, Cory BJ, et al (2000) Use of C reactive protein to guide duration of empiric antibiotic therapy in suspected early neonatal sepsis. Pediatr Infect Dis J 19:531–5 [CrossRef] [PubMed] [Google Scholar]
  • Jaswal RS, Kaushal RK, Goel A, et al (2003) Role of C reactive protein in deciding duration of antibiotic therapy in neonatal septicemia. Indian Pediatr 40:880–3 [PubMed] [Google Scholar]
  • Quenot JP, Luyt CE, Roche N, et al (2013) Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy. Ann Intensive Care 3:21 [CrossRef] [PubMed] [Google Scholar]
  • Oliveira CF, Botoni FA, Oliveira CR, et al (2013) Procalcitonin versus C reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit Care Med 41:2336–43 [CrossRef] [PubMed] [Google Scholar]
  • Simon L, Gauvin F, Amre DK, et al (2004) Serum procalcitonin and C reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–17 [CrossRef] [PubMed] [Google Scholar]
  • Tang BM, Eslick GD, Craig JC, et al (2007) Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 7:210–7 [CrossRef] [PubMed] [Google Scholar]
  • Uzzan B, Cohen R, Nicolas P, et al (2006) Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 34:1996–2003 [CrossRef] [PubMed] [Google Scholar]
  • Reinhart K, Karzai W, Meisner M (2000) Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care Med 26:1193–200 [CrossRef] [PubMed] [Google Scholar]
  • Bouadma L, Luyt CE, Tubach F, et al (2010) Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375:463–74 [Google Scholar]
  • Layios N, Lambermont B, Canivet JL, et al (2012) Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients. Crit Care Med 40:2304–9 [CrossRef] [PubMed] [Google Scholar]
  • Annane D, Maxime V, Faller JP, et al (2013) Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open pii: e002186 [Google Scholar]
  • Verduri A, Luppi F, D'Amico R, et al (2015) Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. PLoS One 10:e0118241 [CrossRef] [PubMed] [Google Scholar]
  • Schuetz P, Briel M, Mueller B (2013) Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections. JAMA 309:717–8 [CrossRef] [PubMed] [Google Scholar]
  • Jensen JU, Hein L, Lundgren B, et al (2011) Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 39:2048–58 [CrossRef] [PubMed] [Google Scholar]
  • Shehabi Y, Sterba M, Garrett PM, et al (2014) Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med 190:1102–10 [CrossRef] [PubMed] [Google Scholar]
  • Harbarth S, Holeckova K, Froidevaux C, et al (2001) Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 164:396–402 [CrossRef] [PubMed] [Google Scholar]
  • Luyt CE, Combes A, Reynaud C, et al (2008) Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med 34:1434–40 [CrossRef] [PubMed] [Google Scholar]
  • Stolz D, Smyrnios N, Eggimann P, et al (2009) Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 34:1364–75 [CrossRef] [PubMed] [Google Scholar]
  • Christ-Crain M, Stolz D, Bingisser R, et al (2006) Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174:84–93 [CrossRef] [PubMed] [Google Scholar]
  • Li H, Luo YF, Blackwell TS, et al (2011) Meta-analysis and systematic review of procalcitonin-guided therapy in respiratory tract infections. Antimicrob Agents Chemother 55:5900–6 [CrossRef] [PubMed] [Google Scholar]
  • Schuetz P, Briel M, Christ-Crain M, et al (2012) Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 55:651–62 [CrossRef] [PubMed] [Google Scholar]
  • Prkno A, Wacker C, Brunkhorst FM, et al (2013) Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock — a systematic review and meta-analysis. Crit Care 17:R291 [CrossRef] [PubMed] [Google Scholar]
  • Schuetz P, Christ-Crain M, Thomann R, et al (2009) Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302:1059–66 [CrossRef] [PubMed] [Google Scholar]
  • Briel M, Schuetz P, Mueller B, et al (2008) Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 168:2000–2007; discussion 2007–2008 [CrossRef] [PubMed] [Google Scholar]
  • Albrich WC, Dusemund F, Bucher B, et al (2012) Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in “real life”: an international, multicenter poststudy survey (ProREAL). Arch Intern Med 172:715–22 [CrossRef] [PubMed] [Google Scholar]
  • Heyland DK, Johnson AP, Reynolds SC, et al (2011) Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 39:1792–9 [CrossRef] [PubMed] [Google Scholar]
  • Hochreiter M, Kohler T, Schweiger AM, et al (2009) Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 13:R83 [CrossRef] [PubMed] [Google Scholar]
  • Nobre V, Harbarth S, Graf JD, et al (2008) Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 177:498–505 [CrossRef] [PubMed] [Google Scholar]
  • Schroeder S, Hochreiter M, Koehler T, et al (2009) Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg 394:221–6 [CrossRef] [PubMed] [Google Scholar]
  • Kip MM, Kusters R, IJzerman MJ, et al (2015) A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis. J Med Econ 18:944–53 [CrossRef] [PubMed] [Google Scholar]
  • Dupuy AM, Philippart F, Pean Y, et al (2013) Role of biomarkers in the management of antibiotic therapy: an expert panel review I: currently available biomarkers for clinical use in acute infections. Ann Intensive Care 3:22 [CrossRef] [PubMed] [Google Scholar]
  • Long W, Deng X, Zhang Y, et al (2011) Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 16:819–24 [CrossRef] [PubMed] [Google Scholar]
  • Drozdov D, Schwarz S, Kutz A, et al (2015) Procalcitonin and pyuria-based algorithm reduces antibiotic use in urinary tract infections: a randomized controlled trial. BMC Med 13:104 [CrossRef] [PubMed] [Google Scholar]
  • Huang TS, Huang SS, Shyu YC, et al (2014) A procalcitonin-based algorithm to guide antibiotic therapy in secondary peritonitis following emergency surgery: a prospective study with propensity score matching analysis. PLoS One 9:e90539 [CrossRef] [PubMed] [Google Scholar]
  • Hohn A, Schroeder S, Gehrt A, et al (2013) Procalcitonin-guided algorithm to reduce length of antibiotic therapy in patients with severe sepsis and septic shock. BMC Infect Dis 13:158 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.